Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Biomarkers for Alzheimer’s disease beyond amyloid and tau

Two new biomarkers for Alzheimer’s disease include one in the blood that relates to neurodegeneration and another that reflects blood–brain barrier dysfunction and is identifiable in cerebrospinal fluid analysis.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: New early biomarkers for neurodegeneration.


  1. 1.

    Preische, O. et al. Nat. Med. (2019).

  2. 2.

    Nation, D.A. et al. Nat. Med. (2019).

  3. 3.

    Jansen, W. J. et al. JAMA Psychiatry 75, 84–95 (2018).

    Article  Google Scholar 

  4. 4.

    Ashton, N. J. et al. Biomark Med. 12, 799–812 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Fagan, A. M. et al. Sci. Transl. Med. 6, 226ra230 (2014).

    Article  Google Scholar 

  6. 6.

    Maia, L. F. et al. Sci. Transl. Med. 5, 194re192 (2013).

    Article  Google Scholar 

  7. 7.

    Sato, C. et al. Neuron 98, 861–864 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Okamura, N. et al. Clin. Transl. Imaging 6, 305–316 (2018).

    Article  Google Scholar 

  9. 9.

    Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimers Dement. (NY) 4, 195–214 (2018).

    Google Scholar 

  10. 10.

    Rasmussen, M. K., Mestre, H. & Nedergaard, M. Lancet Neurol. 17, 1016–1024 (2018).

    CAS  Article  Google Scholar 

  11. 11.

    Khalil, M. et al. Nat. Rev. Neurol. 14, 577–589 (2018).

    CAS  Article  Google Scholar 

  12. 12.

    Bergman, J. et al. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Henrik Zetterberg.

Ethics declarations

Competing interests

H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures–based platform company at the University of Gothenburg. J.M.S. has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zetterberg, H., Schott, J.M. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med 25, 201–203 (2019).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing